Treatment should be initiated and normally monitored only under hospital or specialist supervision. Cordarone X Intravenous is indicated only for the treatment of severe rhythm disorders not responding to other therapies or when other treatments cannot be used. Tachyarrhythmias associated with Wolff-Parkinson-White syndrome. All types of tachyarrhythmias including supraventricular, nodal and ventricular tachycardias; atrial flutter and fibrillation; ventricular fibrillation; when other drugs cannot be used. Cordarone X Intravenous can be used where a rapid response is required or where oral administration is not possible.
Treatment should be initiated and normally monitored only under hospital or specialist supervision. Oral amiodarone hydrochloride is indicated only for the treatment of severe rhythm disorders not responding to other therapies or when other treatments cannot be used. Tachyarrhythmias associated with Wolff-Parkinson-White Syndrome. Atrial flutter and fibrillation when other drugs cannot be used. All types of tachyarrhythmias of paroxysmal nature including: supraventricular, nodal and ventricular tachycardias, ventricular fibrillation: when other drugs cannot be used.
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy.
The purpose of this study is to determine the safety and efficacy of intravenous administration of intermittent doses of levosimendan compared to placebo in ambulatory patients with advanced chronic heart failure.
Tesaro has submitted a New Drug Application (NDA) for an intravenous formulation of Varubi (rolapitant), for nausea, to the FDA....
European approval has been given to United Therapeutics Corp for the intravenous formulation of its prostacyclin vasodilator, Remodulin (treprostinil), to...
Green Cross Corporation announced that the FDA has accepted for review the Company's Biologics License Application for IVIG SN (human...
Baudax Bio, Inc. a specialty pharmaceutical company focused on therapeutics for acute care settings, announced that the FDA has set...